Since appearing in late 2019, the SARS-CoV-2 virus has caused sickness and death across the globe. Researchers and scientists have been looking at multiple solutions to treat COVID-19, including repurposing approved pharmaceutical drugs. One such preexisting drug that offers promise as a possible treatment option is called Ebselen.
A team of researchers at the Pritzker School of Molecular Engineering at the University of Chicago used state-of-the-art computer simulations to explain how Ebselen may counteract the virus. Their findings, which could help provide new avenues to boost Ebselen’s effectiveness as well as suggest approaches for other drugs, appear in a paper published Aug. 14 in the journal Science Advances.